These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 20643159

  • 1. Reducing endocannabinoid metabolism with the fatty acid amide hydrolase inhibitor, URB597, fails to modify reinstatement of morphine-induced conditioned floor preference and naloxone-precipitated morphine withdrawal-induced conditioned floor avoidance.
    McCallum AL, Limebeer CL, Parker LA.
    Pharmacol Biochem Behav; 2010 Oct; 96(4):496-500. PubMed ID: 20643159
    [Abstract] [Full Text] [Related]

  • 2. FAAH inhibitor, URB-597, promotes extinction and CB(1) antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats.
    Manwell LA, Satvat E, Lang ST, Allen CP, Leri F, Parker LA.
    Pharmacol Biochem Behav; 2009 Nov; 94(1):154-62. PubMed ID: 19698735
    [Abstract] [Full Text] [Related]

  • 3. Development, extinction and reinstatement of morphine withdrawal-induced conditioned place aversion in rats.
    Li Y, Liu X, Chen H, Deng H, Xiang X, Chen H, Hao W.
    Addict Biol; 2007 Sep; 12(3-4):470-7. PubMed ID: 17678507
    [Abstract] [Full Text] [Related]

  • 4. Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice.
    Gamage TF, Ignatowska-Jankowska BM, Muldoon PP, Cravatt BF, Damaj MI, Lichtman AH.
    Drug Alcohol Depend; 2015 Jan 01; 146():7-16. PubMed ID: 25479915
    [Abstract] [Full Text] [Related]

  • 5. Behavioral effects of fatty acid amide hydrolase inhibition on morphine withdrawal symptoms.
    Shahidi S, Hasanein P.
    Brain Res Bull; 2011 Aug 10; 86(1-2):118-22. PubMed ID: 21763761
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative effects of pulmonary and parenteral Δ⁹-tetrahydrocannabinol exposure on extinction of opiate-induced conditioned aversion in rats.
    Manwell LA, Mallet PE.
    Psychopharmacology (Berl); 2015 May 10; 232(9):1655-65. PubMed ID: 25395060
    [Abstract] [Full Text] [Related]

  • 8. Glycyl-glutamine, an endogenous beta-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal.
    Cavun S, Göktalay G, Millington WR.
    J Pharmacol Exp Ther; 2005 Nov 10; 315(2):949-58. PubMed ID: 16079299
    [Abstract] [Full Text] [Related]

  • 9. Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague-Dawley rats.
    Petrie GN, Wills KL, Piscitelli F, Smoum R, Limebeer CL, Rock EM, Humphrey AE, Sheppard-Perkins M, Lichtman AH, Mechoulam R, Di Marzo V, Parker LA.
    Psychopharmacology (Berl); 2019 Sep 10; 236(9):2623-2633. PubMed ID: 30993360
    [Abstract] [Full Text] [Related]

  • 10. CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats.
    Wills KL, Vemuri K, Kalmar A, Lee A, Limebeer CL, Makriyannis A, Parker LA.
    Psychopharmacology (Berl); 2014 Nov 10; 231(22):4291-300. PubMed ID: 24770676
    [Abstract] [Full Text] [Related]

  • 11. Fatty acid amide hydrolase inhibitor URB597 prevented tolerance and cognitive deficits induced by chronic morphine administration in rats.
    Hasanein P, Ghafari-Vahed M.
    Behav Pharmacol; 2016 Feb 10; 27(1):37-43. PubMed ID: 26274041
    [Abstract] [Full Text] [Related]

  • 12. Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis.
    Hasanein P, Shahidi S, Komaki A, Mirazi N.
    Eur J Pharmacol; 2008 Sep 04; 591(1-3):132-5. PubMed ID: 18593578
    [Abstract] [Full Text] [Related]

  • 13. Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
    Johnston TH, Huot P, Fox SH, Wakefield JD, Sykes KA, Bartolini WP, Milne GT, Pearson JP, Brotchie JM.
    J Pharmacol Exp Ther; 2011 Feb 04; 336(2):423-30. PubMed ID: 20966038
    [Abstract] [Full Text] [Related]

  • 14. Effect of footshock stress on place conditioning produced by Δ9-tetrahydrocannabinol and the fatty acid amide hydrolase (FAAH) inhibitor, URB597, in Sprague-Dawley rats.
    DeVuono MV, Wills KL, MacPherson DV, Hrelja KM, Parker LA.
    Psychopharmacology (Berl); 2017 Nov 04; 234(21):3229-3240. PubMed ID: 28803323
    [Abstract] [Full Text] [Related]

  • 15. URB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats.
    Hasanein P, Parviz M, Keshavarz M, Roohbakhsh A.
    Can J Physiol Pharmacol; 2009 Jun 04; 87(6):432-9. PubMed ID: 19526037
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat.
    Cross-Mellor SK, Ossenkopp KP, Piomelli D, Parker LA.
    Psychopharmacology (Berl); 2007 Feb 04; 190(2):135-43. PubMed ID: 17111174
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Expression of c-Fos in the rat central amygdala accompanies the acquisition but not expression of conditioned place aversion induced by withdrawal from acute morphine dependence.
    Jin C, Araki H, Nagata M, Shimosaka R, Shibata K, Suemaru K, Kawasaki H, Gomita Y.
    Behav Brain Res; 2005 Jun 03; 161(1):107-12. PubMed ID: 15904717
    [Abstract] [Full Text] [Related]

  • 20. Total neurochemical lesion of noradrenergic neurons of the locus ceruleus does not alter either naloxone-precipitated or spontaneous opiate withdrawal nor does it influence ability of clonidine to reverse opiate withdrawal.
    Caillé S, Espejo EF, Reneric JP, Cador M, Koob GF, Stinus L.
    J Pharmacol Exp Ther; 1999 Aug 03; 290(2):881-92. PubMed ID: 10411605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.